DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Izaflortaucipir F-18

Generic Name: Izaflortaucipir F-18

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

[18F]PI-2620 Phase 3 Histopathological Study

Phase 3

Recruiting

Posted: 2022/12/08

Sponsor:

Life Molecular Imagi...

Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury

Phase 1

Terminated

Posted: 2022/04/20

Sponsor:

Life Molecular Imagi...

Evaluation Comparing Tau PET Radiotracers, [18F]GTP1 and [18F]PI-2620 or [18F]MK-6240 in Subjects With Normal Cognition or Prodromal to Moderate Alzheimer's Disease

Phase 1

Completed

Posted: 2020/09/28

Sponsor:Genentech, Inc.

Longitudinal Changes of [18F]PI-2620 Positron Emission Tomography in Subjects With Cognitively Normal, Mild Cognitive Impairment and Alzheimer's Disease

Phase 2

Completed

Posted: 2019/04/04

Sponsor:

Jae Seung Kim

Evaluation of [18F]PI-2620 as a Potential Positron Emission Computed Tomography Radioligand for Imaging Tau Protein in the Brain

Early Phase 1

Completed

Posted: 2018/04/27

Sponsor:Asan Medical Center

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

ANKTIVA Receives Permanent J-Code from CMS, Streamlining Reimbursement for Bladder Cancer Treatment

5 months ago

The Centers for Medicare & Medicaid Services (CMS) has assigned a permanent J-code (J9028) for ANKTIVA, effective January 1, 2025, to streamline billing.

AC Immune's Pipeline Advances with Key Milestones in Alzheimer's and Parkinson's Disease

7 months ago

AC Immune's ACI-7104.056 Phase 2 trial for Parkinson's disease is set to report interim safety and immunogenicity data by the end of 2024.

September 2024: FDA Actions Span Diabetes, Neurology, and Rare Diseases

8 months ago

The FDA approved Embecta's tubeless patch pump for insulin delivery in adults with type 1 and type 2 diabetes, offering a 300-unit reservoir based on patient feedback.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy